| Gene symbol | WT1 | Synonyms | AWT1, GUD, NPHS4, WAGR, WIT-2, WT-1, WT33 | Type of gene | protein-coding | |
| Chromosome | 11 | Map location | 11p13 | dbXrefs | Entrez:7490 MIM:607102 HGNC:HGNC:12796 Ensembl:ENSG00000184937 AllianceGenome:HGNC:12796 | |
| Gene perturbation-related omics dataset | PerturbAtlas | PertOrg | |||||
| Description | WT1 transcription factor | |||||
| GTO ID | GTC2801 |
| Trial ID | NCT05066165 |
| Disease | Acute Myeloid Leukemia |
| Altered gene | WT1 |
| Therapeutic/Target gene | Target gene |
| Therapy | TCR-T cell |
| Treatment | NTLA-5001 |
| HLA | HLA-A*02:01 |
| Phase | Phase1|Phase2 |
| Recruitment status | Terminated |
| Title | Phase 1/2a, Single Dose Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia |
| Year | 2021 |
| Country | United States |
| Company sponsor | Intellia Therapeutics |
| Other ID(s) | ITL-5001-CL-001 |
| Cohort1: bone marrow blast count < 5% | |||||||||
|
|||||||||
| Cohort2: bone marrow blast count >= 5% | |||||||||
|
|||||||||